Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04523480 · ClinicalTrials.gov registry record · Phase 3
Testopel ® vs. Generic Testosterone Pellets.
A Phase 3 study of Hypogonadism, sponsored by University of Miami.
- Completed
- Registry status
- Phase 3
- Development phase
- 75
- Enrollment target
- 1
- Study location
NCT04523480: Completed Phase 3 study of Hypogonadism, sponsored by University of Miami.
NCT04523480 is a Phase 3 study of Hypogonadism that has completed, run by University of Miami. The registered enrollment target is 75 participants, below the 117-participant average among 21 other Hypogonadism trials with a reported enrollment target (36% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04523480, a Phase 3 study of Hypogonadism, has completed, sponsored by University of Miami.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 75 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to evaluate changes in vascular parameters in subjects receiving Testopel 75mg (one time) versus subjects receiving Compounded Testosterone pellets 100mg (one time) versus subjects receiving Compounded Testosterone pellets 200mg (one time) to participant with clinical hypogonadism.
Primary Outcome
Changes in serum Testosterone levels are assessed in ng/dL
Conditions Studied
Interventions
- DRUG Testopel 75mg Drug Implant
- DRUG Testopel 100mg Drug Implant
- DRUG Testopel 200mg Drug Implant
Study Locations (1)
Florida
- University of Miami, Department of Urology - Miami
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 75 participants |
| Start Date | 2020-03-12 |
| Est. Completion | 2022-12-20 |
| Phase | Phase 3 |
What the finished NCT04523480 record still lists
NCT04523480 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 75 participants, a relatively small participant target, below the 117-participant average among 21 other Hypogonadism trials with a reported enrollment target (36% lower).
The record links to 1 condition, with Hypogonadism appearing as the primary indexed condition, and to 3 interventions - of which Testopel 75mg Drug Implant is the first listed.
NCT04523480 reports a single indexed study location in Florida.
Frequently Asked Questions
What is clinical trial NCT04523480 about?
NCT04523480 is a clinical study titled "Testopel ® vs. Generic Testosterone Pellets.". The purpose of this study is to evaluate changes in vascular parameters in subjects receiving Testopel 75mg (one time) versus subjects receiving Compounded Testosterone pellets 100mg (one time) versus subjects receiving Compounded Testosterone pellets 200mg (one time) to participant with clinical hy...
What is the current status of trial NCT04523480?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 75 participants. The study started on 2020-03-12. Estimated completion is 2022-12-20.
What conditions does trial NCT04523480 study?
This clinical trial studies the following conditions: Hypogonadism.
What interventions are being tested in trial NCT04523480?
The interventions under investigation include: Testopel 75mg Drug Implant (DRUG), Testopel 100mg Drug Implant (DRUG), Testopel 200mg Drug Implant (DRUG).
Who is sponsoring clinical trial NCT04523480?
This trial is sponsored by University of Miami, which has 721 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04523480 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hypogonadism
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04523480's enrollment target sits among peer trials
75 9th of 21 higher than 12 of 21 other Hypogonadism trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hypogonadism trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Observation of Environment and Reproductive-Endocrine Effects
RECRUITING
-
Adaptions and Resiliency to Multi-Stressor OpeRations
RECRUITING · Phase 4
-
Inherited Reproductive Disorders
RECRUITING
-
Locomotor Training With Testosterone to Promote Bone and Muscle Health After Spinal Cord Injury
RECRUITING · Phase 2
-
The Effect of Sex Steroid Replacement Therapy in the Hypogonadism and Transgender Active-Duty Population
RECRUITING
-
A Phase 4 Study to Evaluate Adrenal Function in Hypogonadal Men Treated With JATENZO® for 12 Months
ACTIVE NOT RECRUITING · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01535430 · 75 participants
Assessment of Eloquent Function in Brain Tumor Patients
- NCT01542879 · 75 participants · Phase 1
Development of Radiation Free Whole Body Magnetic Resonance (MR) Imaging Technique for Staging Children With Cancer
- NCT02232191 · 75 participants · Phase 2
Immunologic Response to Pneumococcal Polysaccharide Vaccine in Splenic Injury Patients
- NCT02754544 · 75 participants · NA
Electrocorticography in Mapping Functional Brain Areas During Surgery in Patients With Brain Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI